SBRI Healthcare is an Accelerated Access Collaborative funded initiative providing financial support to innovators developing solutions for the NHS.
Portfolio
4
companies
Upfront Diagnostics
Upfront Diagnostics develops rapid point-of-care blood tests for the rapid detection of strokes.
52 North Health
52 North Health develops portable diagnostic devices to improve care for cancer patients.
Mogrify
Mogrify develops in vivo reprogramming therapies to transform patient outcomes in degenerative diseases.
Chondrogenix
Chondrogenix develops regenerative cartilage therapy for osteoarthritis patients.
The seed round was led by APEX Ventures Medical Fund with backing from SBRI Healthcare and the Stroke Association.
"With this significant funding, we are poised to transform stroke diagnosis worldwide and make a tangible impact on patient care."
SBRI Healthcare backs Cambridge medical device developer with a Phase II award.
"We are privileged to have the support of the SBRI Healthcare programme and are committed to working with our world-leading collaborators to deliver on our ambitions to improve the care of cancer patients."
The Phase II grant from SBRI Healthcare will fund pre-clinical safety and efficacy studies for regenerative cartilage treatments.
"We select projects strategically based on both commercial and scientific considerations and are delighted with the progress of this collaboration with Dr. Wael Kafienah’s laboratory at the University of Bristol. The continued support for our lead musculoskeletal asset from SBRI Healthcare has not only allowed us to reach this phase but will enable us to carry the chondrocyte conversions through to the next stage."
The company has obtained capital from the NHS England funded initiative to support pre-clinical development.
"After several years of research in collaboration with Mogrify, it is great to see our transdifferentiated cartilage cells gain commercial traction from grants such as the SBRI Healthcare and (pre-)clinical partners."
